Technology ID
TAB-4955

SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies

Lead Inventor
Graham, Barney (NIAID)
Co-Inventors
Wang, Lingshu (NIAID)
Mascola, John (NIAID)
Corbett, Kizzmekia (NIAID)
Applications
Vaccines­­­
Therapeutics
Research Materials
Therapeutic Areas
Infectious Disease
Development Status
Research material
Research Products
Plasmids/Vectors
Lead IC
NIAID
ICs
NIAID

NIAID scientists have developed plasmids that allow for production of pseudoviruses expressing SARS-CoV-2 spike protein. As SARS-CoV-2 is a lethal airborne virus, it must be handled in high-containment Biosafety Level 3 (BSL-3) laboratories that require strict airflow, ventilation and decontamination procedures. The pseudotyping plasmids of this invention provide a secure platform for exploring SARS-CoV-2 dynamics without the need for high-risk handling of live virus and ensure a controlled environment for scientists to study SARS-CoV-2 more expeditiously in standard Biosafety Level 2 (BSL -2) laboratories. The plasmids can be used for diverse SARS-CoV-2 research applications, including the study of newly emerging or potential future variants of interest.

Commercial Applications
  • Research material that can be used in the development of neutralization assays
Competitive Advantages
  • Expedite SARS-CoV-2 related experiments by enabling them to be conducted in laboratories with a lower Biosafety Level (BSL-2) than that required for handling SARS-CoV-2 (BSL-3)